Novel YOF-Based Theranostic Agents with a Cascade Effect for NIR-II Fluorescence Imaging and Synergistic Starvation/Photodynamic Therapy of Orthotopic Gliomas

Lv, Zhijia; Jin, Longhai; Gao, Weihao; Cao, Yue; Zhang, Hao; Xue, Dongzhi; Yin, Na; Zhang, Tianqi; Wang, Yinghui; Zhang, Hongjie

doi:10.1021/acsami.2c05354

Cited by 21 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…developed the novel theranostic nanoagents (YMIGL) composed of YOF: Nd 3+ as NIR fluorescence imaging probes, MnO 2 as oxygen generator, ICG as photosensitizer, glucose oxidase (GOx) as energy‐consuming substance, and lactoferrin as targeting molecule for orthotopic glioblastoma therapy. [ 97 ] When YMIGL was endocytosed by glioblastoma cells, the GOx consumed glucose and produced gluconic acid and H 2 O 2 , which could cause a significant upregulation of H 2 O 2 levels and acidity in the environment, leading to the generation of oxygen via degrading MnO 2 shell. ICG was activated by 808 nm laser to generate amount of ROS, which was greatly enhanced by oxygen generation.…”

Section: Nir Light Responsive Materials For Effective Therapy Of Brai...mentioning

confidence: 99%

Advances of NIR Light Responsive Materials for Diagnosis and Treatment of Brain Diseases

Xue

Wang

Zhang

2023

Advanced Optical Materials

Self Cite

View full text Add to dashboard Cite

Generally, brain diseases could be classified into various types. [2] The first is brain tumors, such as malignant glioblastoma, which grows invasively and destroys deep structures. The second type is brain trauma, i.e., traumatic brain injury (TBI), [3] which could cause multiple secondary injuries, including neuroinflammation, blood brain barrier (BBB) damage, and brain edema. The brain vascular diseases are an important type of brain diseases, such as strokes, which can induce a range of dysfunction due to the severe damage to the motor and sensory central nervous system (CNS). Besides, neurodegenerative diseases such as Alzheimer's disease (AD) can result in an irreversible damage to brain tissues owing to the loss of neurons and myelin sheath over time. However, due to the unclear pathogenesis and the obstacle of BBB in CNS, precise imaging diagnosis and effective therapy of brain diseases still remain a great challenge till now. [4] Hence, it is an urgent need to develop the noninvasive, efficient, and convenient techniques for precise imaging and effective therapy of brain diseases. In recent years, the optical materials have attracted great attention in the field of bioapplications, [5] but the limited penetration depth of common used excitation lights (ultraviolet or visible lights, UV-Vis) leads to their applications only in some superficial diseases, such as skin or oral tumors. [6] Currently, it has been reported that the near infrared (NIR) lights exhibit much deeper tissue penetration depth than that of UV-Vis lights, [7] especially penetrate the skull, which makes them possible for imaging and therapy of brain diseases. Hence, exploring NIR light responsive materials is a promising way for achieving precise diagnosis and efficient therapy of brain diseases. [8,9] In terms of imaging, photoacoustic (PA) imaging and the fluorescence imaging are the major imaging techniques responding to NIR lights. PA imaging integrates the advantages of NIR light and ultrasound, achieving biological imaging with deep tissue penetration depth (≈6 cm) and high contrast and resolution. [10] Besides, the lower scattering and autofluorescence of tissues in NIR region endow NIR fluorescence imaging with high sensitivity and signal-to-noise ratio (SNR). [11,12] Indocyanine green (ICG), a NIR molecule dye, was used as NIR fluorescence imaging probe in 1955 and approved by Food and Drug Administration (FDA) for clinic in 1959, but it suffered from the poor photostability and short blood circulation.

show abstract

Section: Nir Light Responsive Materials For Effective Therapy Of Brai...mentioning

confidence: 99%

Advances of NIR Light Responsive Materials for Diagnosis and Treatment of Brain Diseases

Xue

Wang

Zhang

2023

Advanced Optical Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…In 2022, Lv et al designed diagnostic and theranostic nanoplatforms, which consisted of YOF:Nd 3+ with NIR-II emission as the core, MnO 2 as shell, photosensitizer ICG, glucose oxidase (GOx) and lactoferrin with BBB penetration and targeted capabilities (YOF:Nd 3+ @MnO2-ICG-GOx-LF, YMIGL) for NIR II-guided synergistic starvation, and PDT therapy of orthotopic GBM. 87 GOx can consume glucose to produce H 2 O 2 and gluconic acid to achieve starvation treatment at the tumor sites, 88 and the O 2 concentration in situ was enhanced through the cascade reaction between GOx and MnO 2 to improve therapeutic efficiency of PDT. NIR-II fluorescence imaging of orthotopic GBM revealed that YMIGL can effectively penetrate the BBB and accumulate in the tumor region compared to YMIG without targeted peptide.…”

Section: Treatment Of Gbm By Pdtmentioning

confidence: 99%

Image‐guided diagnosis and treatment of glioblastoma

Bian

Wang

Chen

et al. 2023

VIEW

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive primary brain tumor with poor prognosis and high recurrence rate. The presence of the blood–brain barrier (BBB) prevents diagnostic and therapeutic drugs from penetrating and working in GBM. In traditional surgical treatment, it is difficult to completely distinguish the boundary between tumor and surrounding normal tissue, resulting in incomplete resection of tumor. Therefore, the diagnosis and treatment of GBM are very challenging. Several molecular probes and nanoprobes have been reported to successfully penetrate the BBB, selectively target and accumulate in GBM to achieve in situ imaging of brain tumors, thus achieving accurate diagnosis and treatment of orthotopic or non‐orthotopic GBM. This paper reviews the advances of molecular probes and nanoprobes in image‐guided diagnosis and treatment of GBM. The design principle, application, and advantages of each probe are enumerated in detail. Finally, the prospects and potential challenges of probes in the diagnosis and treatment of GBM are discussed with a view to further promote the study and application of novel imaging probes in GBM.

show abstract

“…However, several challenges remain, such as the accurate detection of cancer metastasis at the preoperative or even intraoperative stage and improvement of the spatial and temporal resolution. Although the NIR-II spectra is available for through-skull penetration in vivo , the poor capacity of NIR-II nano-systems for crossing the BBB significantly limits the imaging contrast and therapeutic efficacy for glioma detection ( Zhang H. et al, 2022 ; Lv et al, 2022b ; Men et al, 2022 ). By equipping fluorescent probes with targeted delivery systems, the accumulation of NIR agents at glioma tumor sites can be improved.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Recent advances in NIR-II fluorescence based theranostic approaches for glioma

Ling¹,

Yao²

2022

Front. Chem.

View full text Add to dashboard Cite

Gliomas are among the most common malignant tumors in the central nervous system and lead to poor life expectancy. However, the effective treatment of gliomas remains a considerable challenge. The recent development of near infrared (NIR) II (1000–1700 nm) theranostic agents has led to powerful strategies in diagnosis, targeted delivery of drugs, and accurate therapy. Because of the high capacity of NIR-II light in deep tissue penetration, improved spatiotemporal resolution can be achieved to facilitate the in vivo detection of gliomas via fluorescence imaging, and high contrast fluorescence imaging guided surgery can be realized. In addition to the precise imaging of tumors, drug delivery nano-platforms with NIR-II agents also allow the delivery process to be monitored in real-time. In addition, the combination of targeted drug delivery, photodynamic therapy, and photothermal therapy in the NIR region significantly improves the therapeutic effect against gliomas. Thus, this mini-review summarizes the recent developments in NIR-II fluorescence-based theranostic agents for glioma treatment.

show abstract

Novel YOF-Based Theranostic Agents with a Cascade Effect for NIR-II Fluorescence Imaging and Synergistic Starvation/Photodynamic Therapy of Orthotopic Gliomas

Cited by 21 publications

References 32 publications

Advances of NIR Light Responsive Materials for Diagnosis and Treatment of Brain Diseases

Advances of NIR Light Responsive Materials for Diagnosis and Treatment of Brain Diseases

Image‐guided diagnosis and treatment of glioblastoma

Recent advances in NIR-II fluorescence based theranostic approaches for glioma

Contact Info

Product

Resources

About